Nautilus Biotechnology (NAUT) Q3 2024 earnings summary

Executive summary

• The company is developing a single-molecule proteome analysis platform with a focus on proteoform detection, notably tau protein for Alzheimer's research, and aims to revolutionize biomedicine and unlock a $55B+ market by 2027.

• Platform readiness is demonstrated by successful integration of assay, hardware, and software, but broad-scale protein quantification milestones are delayed due to probe development challenges.

• Strategic collaborations with Genentech, Amgen, MD Anderson, and TGen are advancing applications in oncology, rare diseases, and drug discovery, with ongoing engagement at scientific conferences.

• The company remains in the collaboration phase, with no commercial products or revenue to date, and expects limited revenue until a broader commercial launch planned for late 2025.

• Appointed a new Chief Marketing Officer to strengthen commercialization and customer engagement.

Financial highlights

• Q3 2024 net loss was $16.4 million, with a nine-month net loss of $53.2 million and accumulated deficit of $255.4 million.

• Operating expenses for Q3 2024 were $19.1 million, flat year-over-year and $1.7 million below the previous quarter.

• Research and development expenses rose to $37.7 million for the nine months ended September 30, 2024.

• Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024, with cash burn of $11.7 million in Q3 and $44.8 million for the nine months.

• No revenue was generated in the reporting period.

Outlook and guidance

• Commercial launch of the broad-scale proteome analysis platform is targeted for late 2025, with early access programs and proof-of-concept studies ongoing.

• Proteoform capabilities, especially for tau, will be proven out with pharma and academic partners in the first half of 2025.

• Operating expense growth for full year 2024 expected at ~10%, better than previous guidance.

• Cash runway is projected into 2027, but additional capital will likely be needed for long-term growth.

• The company expects to continue incurring significant losses as it advances R&D and prepares for commercialization.